Latest Patents News

Page 5 of 104
White Energy has pivoted towards thermal and metallurgical coal, completed two acquisitions and raised $15 million after year end. But its FY2026 report records a $3.6 million normalised EBITDA loss, just $0.4 million in unrestricted cash and an auditor-highlighted material uncertainty over going concern.
Victor Sage
Victor Sage
27 Oct 2026
Botanix’s Sofdra prescriptions rose 5.3% in the September quarter, but flat net revenue and a sharp cash decline have forced a major reset. The company is targeting a roughly 50% reduction in operating expenses while assessing licensing, acquisitions and broader strategic transactions.
Victor Sage
Victor Sage
27 Oct 2026
Aruma Resources has agreed to acquire a 90% interest in a patented mineral right at its Tillex project in Ontario, extending the interpreted copper-silver trend by 760 metres. The C$30,000 acquisition adds an untested near-term drilling target while assays from the company’s ongoing Phase 2 program remain pending.
Maxwell Dee
Maxwell Dee
27 Oct 2026
Foresta has secured acceptance of a Japanese patent for its rosin and terpene extraction technology while moving the Kawerau pine chemicals project through front-end design. But with $2.47 million in cash and estimated funding for 2.65 quarters, the next development stage will bring a financing question into sharper focus.
Victor Sage
Victor Sage
26 Oct 2026
Invex Therapeutics has agreed to acquire New Zealand biotech Rekover Therapeutics for shares and performance rights, adding a planned Phase 2a multiple sclerosis trial to its neurology portfolio. The transaction is paired with a $10 million placement, but would substantially expand the company’s share count and requires shareholder approval.
Ada Torres
Ada Torres
26 Oct 2026
Island Pharmaceuticals has secured approvals to use Galidesivir in Uganda’s Bundibugyo Ebola outbreak while advancing two complementary Marburg studies and expanding manufacturing. The progress comes with a sharper funding question: cash fell to A$7.83 million after quarterly operating outflows of A$4.93 million, leaving an estimated 1.6 quarters of funding.
Victor Sage
Victor Sage
26 Oct 2026
Mayne Pharma’s unaudited first-quarter revenue fell 2% to A$95.7 million, while underlying EBITDA dropped 52% as generic competition hit Dermatology. Strong prescription growth in Women’s Health and DistributeRx offered a partial counterweight, alongside progress on key legal disputes.
Victor Sage
Victor Sage
26 Oct 2026
Biome Australia has reported record pharmacy sell-through, further market-share gains and positive operating cash flow as it begins manufacturing Activated Probiotics domestically. The quarter also moved its China expansion and BMB18 clinical trial closer to key execution milestones.
Ada Torres
Ada Torres
26 Oct 2026
Perpetual Resources has returned selective underground tungsten assays of up to 12.03% WO₃ at its Nevada Scheelite project, with eight of nine underground samples above 1%. The results are encouraging but do not yet establish grade continuity, mineralised widths or a resource.
Maxwell Dee
Maxwell Dee
26 Oct 2026
Identitii has lodged a prospectus for up to 4.435 million free options, designed to give shareholders a way to partly offset dilution from its convertible note funding. The offer costs nothing upfront, but the options are unquoted, time-limited and sit alongside a funding package that still has $2.4 million to be received.
Victor Sage
Victor Sage
23 Oct 2026
New research from the NEPTUNE cohort has strengthened the biological rationale for Dimerix’s DMX-200 kidney drug, linking CCR2 activity and urinary MCP-1 levels with poorer outcomes in FSGS. The findings support the drug’s mechanism, but do not yet demonstrate Phase 3 efficacy.
Ada Torres
Ada Torres
23 Oct 2026
Zoono Group is seeking up to A$1.61 million from a non-renounceable rights issue after completing a separate A$250,000 placement, with its offer document warning of material uncertainty around going concern. The funds are intended to support shelf-life extension projects, intellectual property and working capital, but investors face dilution and an unresolved legal case.
Ada Torres
Ada Torres
23 Oct 2026

Browse the archive

Full archive